CenterBook Partners LP Raises Stock Position in Cencora, Inc. $COR

CenterBook Partners LP lifted its stake in Cencora, Inc. (NYSE:COR) by 56.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,722 shares of the company’s stock after purchasing an additional 2,797 shares during the period. CenterBook Partners LP’s holdings in Cencora were worth $2,608,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Manchester Capital Management LLC grew its holdings in shares of Cencora by 3.0% during the 4th quarter. Manchester Capital Management LLC now owns 2,789 shares of the company’s stock worth $942,000 after acquiring an additional 81 shares during the period. Hilton Head Capital Partners LLC bought a new stake in shares of Cencora during the fourth quarter valued at approximately $77,000. Fiera Capital Corp grew its stake in Cencora by 8.6% in the fourth quarter. Fiera Capital Corp now owns 38,066 shares of the company’s stock worth $12,857,000 after purchasing an additional 3,001 shares during the period. JPMorgan Chase & Co. raised its holdings in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock worth $1,682,859,000 after purchasing an additional 304,760 shares in the last quarter. Finally, ING Groep NV raised its holdings in Cencora by 16.7% in the fourth quarter. ING Groep NV now owns 196,696 shares of the company’s stock worth $66,434,000 after purchasing an additional 28,132 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

COR opened at $279.15 on Wednesday. The company’s 50 day moving average is $291.16 and its 200 day moving average is $329.11. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market cap of $54.31 billion, a price-to-earnings ratio of 21.41, a PEG ratio of 1.48 and a beta of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has approved a share repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Wall Street Analyst Weigh In

COR has been the subject of several research reports. William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Citigroup dropped their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company decreased their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Barclays increased their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.